SENSUS HEALTHCARE INC
SRTSNASDAQTrading Snapshot
- Day Range
- $2.75 β $2.84
- 52-Week Range
- $2.66 β $5.49
- Volume (shares)
- 232
- Avg Volume (shares)
- β
- Shares Outstanding
- 16.5M
- Next Earnings
- 2026-10-29
Fundamentals Snapshot
- Annual Revenue
- $27M
- Last Q Revenue
- $2M
- P/E Ratio
- β
- P/S Ratio
- 2.7x
- EPS (TTM)
- $-0.94
- Dividend Yield
- β
- Dilution (1yr)
- β0.7%
SENSUS HEALTHCARE INC
SRTSAbout SENSUS HEALTHCARE INC
Sensus Healthcare, Inc. operates as a medical technology enterprise, manufacturing and distributing radiation therapy apparatuses to medical institutions across the globe. The company's portfolio leverages superficial radiation therapy (SRT), a cutting-edge low-energy X-ray methodology. Their product line features the SRT-100, a photon X-ray system for low-energy superficial radiotherapy. This device presents a non-surgical alternative for patients dealing with non-melanoma skin cancers, including basal cell and squamous cell carcinomas, alongside other dermatological issues like keloids. Another key offering is the SRT-100 Vision, which incorporates a specialized SRT treatment planning application. This application seamlessly integrates an embedded high-frequency ultrasound imaging module, tools for volumetric tumor analysis, beam margin delineation, and dosimetry parameter configuration. In addition, Sensus Healthcare provides the SRT-100 Plus, the Sentinel service program to ensure system protection for its clients, and options for in-office laser rentals. They also supply various consumable items, such as replacement lead shielding, disposable radiation safety gear like aprons and eye shields, ultrasound probe film, and single-use applicator tips designed to treat lesions of different sizes and on various body areas. Founded in 2010, Sensus Healthcare, Inc. maintains its corporate headquarters in Boca Raton, Florida.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
βLatest News & Updates
News unavailable.